Decide fast. Decide right. 

A rapid assessment designed to provide an initial strategic view of an early-stage asset, molecule or therapeutic hypothesis.

Best for:
Biotech CEOs, investors, business developers and early asset reviewers.

Typical scope:
1–20 molecules

Timeline:
1–2 weeks

Output:
A concise executive report highlighting first signals of activity, safety, developability, red flags, opportunities and a preliminary Go / No-Go / Deep Dive recommendation.

Use it when you need to:
Quickly understand whether an opportunity deserves further scientific, financial or experimental commitment.

Scientific depth for committed decision-making.

A comprehensive and comparative assessment of a drug discovery asset, integrating target biology, molecular activity, selectivity, ADME/Tox, safety pharmacology and strategic interpretation.

Best for:
CSOs, R&D leaders, investment funds, biotech executives and pharma partnering teams.

Typical scope:
10–100 molecules

Timeline:
3–5 weeks

Output:
A detailed decision report including scientific rationale, molecule prioritization, benchmark against references or alternatives, ADME/Tox and Safety Shield 44™ assessment, key risks and recommended next experiments.

Use it when you need to:
Challenge, prioritize or support an asset before internal review, partnering, financing or investment decisions.

From biology to mechanism, up to candidate prioritization.

A dedicated workflow for rare diseases and poorly documented biological contexts, where evidence is fragmented and uncertainty is high.

Best for:
Rare disease biotechs, translational research teams, innovation groups, CSOs and specialized investors.

Typical scope:
50–500 evaluated molecules or hypotheses

Timeline:
4–7 weeks

Output:
A rare disease-oriented report covering disease biology, genetic and mechanistic context, target rationale, candidate prioritization and optional in silico generation to expand therapeutic options.

Use it when you need to:
Move from a rare disease mechanism or genetic hypothesis toward actionable therapeutic strategies and candidate options.

Generate. Evaluate. Prioritize.

A generative AI and evaluation workflow designed to explore new chemical options, prioritize candidate molecules and accelerate early discovery cycles.

Best for:
Discovery teams, CSOs, medicinal chemistry teams and R&D innovation groups.

Typical scope:
500–10,000 generated or evaluated molecules

Timeline:
6–10 weeks

Output:
Candidate Sprint deliverables may include:
AI-generated molecular structures, SMILES export, ranked candidate shortlist, activity and selectivity prediction table, ADMET/Tox and Safety Shield 44™ risk profile, novelty and similarity assessment, out-of-domain confidence flags, synthesis-prioritization recommendations, executive summary for R&D or investor review

Use it when you need to:
Explore new molecular directions, reduce failure risk and focus experimental resources on the most promising candidates.

A long-term scientific and decision-support partnership.

A flexible collaboration model for teams requiring recurring analyses, dedicated support, regular decision dashboards or continuous program derisking.

Best for:
Growing biotechs, pharma teams, venture funds and strategic R&D partners.

Timeline:
3–12 months

Output:
Recurring reports, dashboards, strategic reviews, prioritized recommendations and tailored scientific support.

Use it when you need to:
Build a sustained decision-support capability across multiple assets, programs or investment opportunities.

Depending on project needs, Genmap-Pro™ assessments can include:

• traceability and auditability pack
• advanced Safety Shield 44™ assessment
• structure-based docking and modeling
• dedicated AI generation or fine-tuning
• executive presentation for CEOs, CSOs, investors or boards.